US Stock MarketDetailed Quotes

KPTI Karyopharm Therapeutics

Watchlist
  • 6.480
  • +0.130+2.05%
Trading Apr 30 11:04 ET
55.53MMarket Cap-0.46P/E (TTM)

Karyopharm Therapeutics Key Stats

Karyopharm Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 6 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 38.390M--
--2025/Q1-- / 35.122M--
Feb 19, 20252024/Q430.542M / 35.674M--
Nov 5, 20242024/Q338.783M / 37.924M--
Aug 6, 20242024/Q242.786M / 36.213M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 38.390M--
--2025/Q1-- / 35.122M--
Feb 19, 20252024/Q430.542M / 35.674M--
Nov 5, 20242024/Q338.783M / 37.924M--
Aug 6, 20242024/Q242.786M / 36.213M--

Unlock Free Earnings Estimates

Karyopharm Therapeutics Earnings Reports

Read more

Market Insights

Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Unlock Now

Discussing

Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More